welcome
BQPrime

BQPrime

Business

Business & Economics

Natco Pharma Q2 Results Review - Ex-Revlimid Growth Healthy; Valuation Attractive: ICICI Securities

BQPrime
Summary
Nutrition label

79% Informative

We raise our rating on the stoc 'Add' 'Add' and revise our target pric Rs 875 s 875.

Revenue growth of 139%/65% for Q2/H1 FY24 was mainly driven by exports.

Management has retained FY24 prof India ter tax estimate of Rs 10-12 billion.

Windfall is invested in research and development (8-10% of sales) to build generic pharma and agrochemical pipeline. ICICI Securities Report g Natco Pharma Ltd. n class="summaryFeed_highLightText__NxlGi">DISCLAIMER 139%/65% Light Q2 xt__NxlGi">Rs 875 'Add' < 56%/54% ass="summaryFeed_highLightText__NxlGi">Natco Rs 10-12 billion d_highLightText__ Rs 7.9 billion /span> gRevlimid ryFeed_highLightText__NxlGi">F483 8-10% class="summaryFeed_highLightText__NxlGi">The ~9% Q2 2-3%

VR Score

89

Informative language

92

Neutral language

89

Article tone

formal

Language

English

Language complexity

40

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

long-living

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links